In patients with mild or moderate chronic kidney disease, renin–angiotensin system inhibitors have improved outcomes, but less evidence supports their use in advanced CKD. New research findings are ...
a Multivariate model adjusting for cancer therapy including antimetabolites, Vascular endothelial growth factors inhibitors, taxanes, tyrosine kinase inhibitors, monoclonal antibodies, vinca alkaloids ...
Cost-effectiveness of NALIRIFOX compared to other first-line treatments for metastatic pancreatic cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This ...
The trial compares sparsentan, an oral pill developed by Travere Therapeutics, Inc., with the standard angiotensin receptor blocker irbesartan. Both drugs aim to slow kidney damage in focal segmental ...
Scientists have discovered a new generation of angiotensin receptor blockers that may be used to treat coronavirus disease 2019 (COVID-19). In silico docking and molecular dynamics studies have shown ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results